Indivior PLC (INDV)
Indivior Pharmaceuticals Inc. focuses on developing and selling buprenorphine-based prescription drugs for opioid dependence treatment. With a strong presence in the US, UK, and Rest of World, they offer Suboxone Film, Suboxone Tablet, and Subutex Tablet.
Company Overview
Indivior Pharmaceuticals offers a focused investment opportunity in addiction treatment, leveraging its established Suboxone franchise and 82.8% gross margin to address the opioid crisis. With a P/E ratio of 25.94 and a $4.30B market cap, Indivior presents growth potential in a critical healthcare segment.
Investment Thesis
Indivior presents a compelling investment opportunity within the addiction treatment space. With a market capitalization of $4.30 billion and a solid gross margin of 82.8%, the company demonstrates financial stability and profitability. The increasing focus on addressing the opioid crisis globally serves as a significant tailwind for Indivior's buprenorphine-based products. Key value drivers include the continued adoption of medication-assisted treatment (MAT) and the expansion into co-occurring disorders and other substance use disorders. Growth catalysts include potential regulatory approvals for new formulations and increased market penetration in international markets. The company's P/E ratio of 25.94 suggests a reasonable valuation relative to its earnings. Investors should consider Indivior for its potential to generate sustainable revenue growth and contribute to solving a critical public health issue. The company's commitment to innovation and advocacy further strengthens its long-term prospects.
Key Highlights
- Market Cap of $4.30B reflects strong investor confidence in Indivior's market position.
- Gross Margin of 82.8% indicates efficient operations and strong pricing power.
- Profit Margin of 14.1% demonstrates the company's ability to convert revenue into profit.
- P/E Ratio of 25.94 suggests a reasonable valuation compared to industry peers.
- Focus on buprenorphine-based drugs positions Indivior at the forefront of opioid dependence treatment.
Competitors
Strengths
- Established brand recognition with Suboxone.
- High gross margin of 82.8%.
- Focus on a critical healthcare need: opioid dependence treatment.
- Global presence in key markets.
Weaknesses
- Reliance on buprenorphine-based products.
- Exposure to generic competition.
- Regulatory risks associated with pharmaceutical products.
- Potential for product liability claims.
Catalysts
- Ongoing: Continued efforts to combat the opioid crisis and expand access to treatment.
- Upcoming: Potential regulatory approvals for new formulations of buprenorphine.
- Ongoing: Expansion into co-occurring disorders and other substance use disorders.
- Ongoing: Increased adoption of medication-assisted treatment (MAT) programs.
Risks
- Potential: Increasing competition from generic versions of Suboxone.
- Potential: Changes in government regulations and reimbursement policies.
- Ongoing: Litigation risks related to opioid addiction.
- Potential: Negative publicity impacting brand reputation.
- Ongoing: Dependence on a limited number of products.
Growth Opportunities
- Expansion into Co-occurring Disorders: Indivior has the opportunity to expand its product offerings to address co-occurring mental health disorders alongside opioid dependence. This represents a significant market opportunity, as many individuals struggling with addiction also experience depression, anxiety, or other mental health conditions. By developing integrated treatment solutions, Indivior can capture a larger share of the mental health market and improve patient outcomes. The market size for mental health treatments is substantial and growing, offering a long-term growth avenue for Indivior.
- Geographic Expansion: Indivior can pursue growth by expanding its presence in international markets. While the company already operates in the United States, United Kingdom, and Rest of World, there are opportunities to enter new regions with high rates of opioid dependence and limited access to treatment. This expansion could involve establishing partnerships with local distributors, seeking regulatory approvals for its products, and investing in marketing and sales efforts. The timeline for geographic expansion will depend on regulatory processes and market conditions in each target region.
- Development of Novel Formulations: Indivior can invest in the development of novel formulations of buprenorphine to improve patient adherence and convenience. This could include long-acting injectable formulations or alternative delivery methods. By offering innovative products, Indivior can differentiate itself from competitors and capture a larger share of the market. The timeline for developing and launching new formulations will depend on the complexity of the research and development process and regulatory requirements.
- Strategic Partnerships and Acquisitions: Indivior can pursue strategic partnerships and acquisitions to expand its product portfolio and market reach. This could involve partnering with other pharmaceutical companies, biotech firms, or healthcare providers. Acquisitions could provide access to new technologies, products, or markets. By pursuing strategic collaborations, Indivior can accelerate its growth and strengthen its competitive position. The timeline for partnerships and acquisitions will depend on market conditions and the availability of suitable targets.
- Increased Focus on Advocacy and Education: Indivior can further invest in advocacy and education efforts to reduce the stigma associated with addiction and promote access to treatment. This could involve partnering with patient advocacy groups, healthcare organizations, and government agencies. By raising awareness and educating the public about addiction, Indivior can help to increase demand for its products and improve patient outcomes. These efforts can contribute to a more supportive environment for individuals seeking treatment and reduce barriers to access.
Opportunities
- Expansion into co-occurring disorders.
- Geographic expansion into new markets.
- Development of novel formulations.
- Strategic partnerships and acquisitions.
Threats
- Increasing competition from generic drug manufacturers.
- Changes in government regulations and reimbursement policies.
- Negative publicity or litigation related to opioid addiction.
- Economic downturn impacting healthcare spending.
Competitive Advantages
- Established brand recognition with Suboxone.
- Proprietary formulations of buprenorphine-based medications.
- Strong relationships with healthcare providers in the addiction treatment space.
- Regulatory expertise in obtaining approvals for addiction treatment drugs.
About
Indivior Pharmaceuticals Inc., established on September 26, 2014, is a holding company dedicated to the development, manufacture, and sale of buprenorphine-based prescription drugs aimed at treating opioid dependence. Headquartered in North Chesterfield, VA, the company's portfolio includes Suboxone Film, Suboxone Tablet, and Subutex Tablet, all designed to aid in the management of opioid addiction. Indivior operates across three key geographical segments: the United States, the United Kingdom, and the Rest of World, reflecting its global reach and commitment to addressing the opioid crisis on an international scale. Since its inception, Indivior has focused on providing evidence-based treatments for opioid use disorder. The company's flagship product, Suboxone, has played a significant role in medication-assisted treatment (MAT) programs. Indivior's commitment extends beyond medication, as they actively engage in advocacy and education to reduce the stigma associated with addiction and promote access to treatment. The company's financial performance, marked by a $4.30 billion market capitalization and a 14.1% profit margin, underscores its strong position within the specialty pharmaceutical market. Indivior continues to innovate and expand its offerings to meet the evolving needs of patients and healthcare providers in the field of addiction treatment.
What They Do
- Develop buprenorphine-based prescription drugs.
- Manufacture medications for opioid dependence treatment.
- Sell Suboxone Film for opioid addiction.
- Offer Suboxone Tablets as an alternative treatment option.
- Provide Subutex Tablets for managing opioid withdrawal symptoms.
- Operate in the United States, United Kingdom, and Rest of World.
- Focus on medication-assisted treatment (MAT) for opioid use disorder.
Business Model
- Develop, manufacture, and sell branded buprenorphine-based medications.
- Generate revenue through prescription drug sales.
- Focus on the opioid dependence treatment market.
- Operate through a global distribution network.
Industry Context
Indivior operates within the specialty pharmaceutical industry, specifically focusing on addiction treatment. The market for opioid dependence medications is driven by the ongoing opioid crisis and increasing awareness of medication-assisted treatment (MAT). The industry is characterized by regulatory scrutiny, pricing pressures, and the need for continuous innovation. Indivior competes with companies offering alternative addiction treatment options and generic versions of buprenorphine. The global market for addiction treatment is expected to grow, driven by increasing rates of substance abuse and mental health disorders. Indivior's focus on buprenorphine-based therapies positions it as a key player in this evolving landscape.
Key Customers
- Individuals suffering from opioid dependence.
- Healthcare providers prescribing addiction treatment medications.
- Pharmacies dispensing prescription drugs.
- Hospitals and treatment centers offering addiction services.
Financials
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | $307M | $22M | $0.16 |
| Q4 2024 | $299M | $59M | $0.46 |
| Q1 2025 | $266M | $47M | $0.38 |
| Q2 2025 | $302M | $18M | $0.14 |
Source: Company filings
Chart & Info
Price Chart
Indivior PLC (INDV) stock price: $36.25 (+0.52, +1.46%)
Latest News
No recent news available for INDV.
Technical Analysis
Rationale
AI-generated technical analysis for INDV including trend direction, momentum, and pattern recognition.
What to Watch
Key support and resistance levels, volume signals, and upcoming events.
Risk Management
Position sizing, stop-loss levels, and risk-reward assessment.
Community
Discussion
Share your analysis and discuss Indivior PLC (INDV) with other investors. Log in to post.
Sentiment
Community sentiment and discussion activity for INDV.
Make a Prediction
Set your price target for Indivior PLC (INDV), choose a timeframe, and track your prediction accuracy.
Current price: $36.25
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for INDV.
Price Targets
Median: $44.50 (+20.7% from current price)
Insider Flow (30d)
MoonshotScore
Score Factors
-
Revenue Growth 4/100
Revenue grew only 8.7% YoY, suggesting the company is in a slower growth phase.
-
Gross Margin 10/100
Gross margin of 82.8% shows excellent pricing power and a strong competitive moat.
-
Operating Leverage 4/100
Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.
-
Cash Runway 5/100
Cash position data is currently unavailable for this company.
-
R&D Intensity 5/100
R&D spending data is currently unavailable for this company.
-
Insider Activity 6/100
No significant insider buying or selling recently, which is neutral for the stock outlook.
-
Short Interest 10/100
Daily turnover of 1.60% indicates healthy liquidity with smooth entry/exit for investors.
-
Price Momentum 3/100
Weak momentum with few bullish signals. The stock may be in a downtrend or consolidation phase.
-
News Sentiment 5/100
No sentiment data available
What does this score mean?
The MoonshotScore rates INDV's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Frequently Asked Questions
What does Indivior Pharmaceuticals Inc do?
Indivior Pharmaceuticals Inc. is a global pharmaceutical company focused on developing, manufacturing, and selling buprenorphine-based prescription drugs for the treatment of opioid dependence. Their primary product, Suboxone, is a leading medication-assisted treatment (MAT) option. The company operates in the United States, United Kingdom, and other international markets, providing solutions for individuals struggling with opioid addiction. Indivior's business model centers around providing evidence-based treatments and supporting healthcare providers in addressing the opioid crisis.
Is INDV stock a good buy?
INDV stock presents a mixed investment profile. The company's strong gross margin of 82.8% and focus on a critical healthcare need are positive indicators. However, potential risks include generic competition and regulatory changes. Investors should consider the company's growth opportunities, such as expansion into co-occurring disorders and new markets, alongside its financial metrics and competitive landscape. A thorough analysis of Indivior's valuation, growth prospects, and risk factors is essential before making an investment decision.
What are the main risks for INDV?
Indivior faces several key risks, including increasing competition from generic drug manufacturers, which could erode its market share and pricing power. Regulatory changes and potential litigation related to opioid addiction also pose significant threats. The company's reliance on buprenorphine-based products makes it vulnerable to shifts in treatment guidelines or the emergence of alternative therapies. Economic downturns could impact healthcare spending and reduce demand for Indivior's products. Careful monitoring of these risks is crucial for investors.
Is INDV a good stock to buy?
Whether INDV is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.
What is the INDV MoonshotScore?
The MoonshotScore for INDV is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.
How often is INDV data updated?
INDV stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to INDV is aggregated continuously from premium financial news sources throughout the day.
What are the growth catalysts for INDV?
Growth catalysts for Indivior PLC (INDV) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes Indivior PLC's specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.
Who are INDV's main competitors?
Indivior PLC (INDV) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether INDV has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.
What do analysts say about INDV?
Wall Street analyst coverage for INDV includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.
What is INDV's market cap?
Market capitalization (market cap) for INDV is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows INDV's current market cap alongside enterprise value and other valuation metrics.
How has INDV stock performed recently?
INDV's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing INDV's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.
What are the risks of investing in INDV?
Key risk categories for INDV include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures INDV's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.
Are insiders buying or selling INDV?
Insider trading activity for INDV tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.
Is INDV a good stock for beginners?
Indivior PLC (INDV) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.
How risky is INDV for first-time investors?
Every stock carries risk, including Indivior PLC (INDV). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like INDV.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Future performance is not guaranteed.